Connection

Mitzi Nagarkatti to NADPH Oxidase 2

This is a "connection" page, showing publications Mitzi Nagarkatti has written about NADPH Oxidase 2.
Connection Strength

0.695
  1. Higher intestinal and circulatory lactate associated NOX2 activation leads to an ectopic fibrotic pathology following microcystin co-exposure in murine fatty liver disease. Comp Biochem Physiol C Toxicol Pharmacol. 2020 Dec; 238:108854.
    View in: PubMed
    Score: 0.179
  2. Exogenous PP2A inhibitor exacerbates the progression of nonalcoholic fatty liver disease via NOX2-dependent activation of miR21. Am J Physiol Gastrointest Liver Physiol. 2019 10 01; 317(4):G408-G428.
    View in: PubMed
    Score: 0.167
  3. Environmental microcystin targets the microbiome and increases the risk of intestinal inflammatory pathology via NOX2 in underlying murine model of Nonalcoholic Fatty Liver Disease. Sci Rep. 2019 06 19; 9(1):8742.
    View in: PubMed
    Score: 0.166
  4. High circulatory leptin mediated NOX-2-peroxynitrite-miR21 axis activate mesangial cells and promotes renal inflammatory pathology in nonalcoholic fatty liver disease. Redox Biol. 2018 07; 17:1-15.
    View in: PubMed
    Score: 0.152
  5. Micro-RNA 21 inhibition of SMAD7 enhances fibrogenesis via leptin-mediated NADPH oxidase in experimental and human nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 2015 Feb 15; 308(4):G298-312.
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.